小细胞肺癌的免疫治疗研究进展  

Research progress of immunotherapy for small cell lung cancer

作　　者：张欣[1] 葛晖[1] 丁翠敏[1] Zhang Xin;Ge Hui;Ding Cuimin(Department of Respiratory Medicine,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第四医院呼吸内科,石家庄050011

出　　处：《国际呼吸杂志》2021年第11期861-865,共5页International Journal of Respiration

基　　金：北京肿瘤防治研究会科研基金(CAPTRALung2019004)。

摘　　要：肺癌的发病率和病死率在所有恶性肿瘤中呈逐年上升的趋势,其中小细胞肺癌(SCLC)约占所有肺癌的14%。由于SCLC早期不易发现,易复发转移,治疗效果不佳,平均5年生存率不超过10%。曾有研究显示化疗对34%~85%的SCLC有效,但疾病进展迅速,后续二线治疗效果很不理想。随着美国食品药品监督管理局批准卡铂、依托泊苷联合抗程序性细胞死亡配体1抑制剂atezolizumab作为一线治疗,单药抗程序性细胞死亡蛋白1抑制剂nivolumab和pembrolizumab作为三线治疗,免疫检查点抑制剂逐渐进入SCLC的治疗中。现对SCLC免疫治疗的临床研究及生物标志物研究进展进行综述。Among all malignant tumors,the morbidity and mortality of lung cancer are increasing yearly,small cell lung cancer(SCLC)accounts for approximately 14%of all lung cancers.Because SCLC is not easily detected in the early stage,it tends to relapse and metastasize,and has a poor treatment effect,the average five-year survival rate does not exceed 10%.Previous studies have shown that chemotherapy is effective for 34%to 85%of SCLC,but the disease progresses rapidly,and the effect of subsequent second-line treatment is very unsatisfactory.Food and Drug Administration of America approved carboplatin,etoposide and programmed cell death ligand 1 inhibitor atezolizumab as first-line treatment.Programmed cell death protein 1 inhibitors nivolumab and pembrolizumab as monotherapy in third-line treatment.Immune checkpoint inhibitors gradually entered the treatment of SCLC.The clinical research and biomarkers of SCLC immunotherapy are summarized and sorted out.

关 键 词：小细胞肺癌 生物医学研究 生物学标记 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]